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 Melanoma is a neoplasm whose biology we are getting to know better and better. The consequence of this is the latest 
edition of “WHO Classification of Skin Tumours 4th edition, 2018”. The division presented in this paper takes into account 
the character of growth and location of melanoma, but also results from the analysis of the most frequent mutations oc-
curring in this neoplasm. The assessment of the stage of melanoma progression, based on two most important prognostic 
microscopic features, i.e. the depth of infiltration and the presence or absence of ulceration, remains valid. 
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Melanoma, from a clinical and pathological point of view, 
makes up a heterogenous disease entity. The basis for the 
classification of this tumour was worked out  by W.H. Clark [1] 
and V.J. McGovern [2] in the 1970s. The classification which 
they proposed presents melanoma as a melanocytic lesion, 
which, within its development, undergoes progression. The 
first stage is defined as melanoma in situ. This type of melano-
ma is characterised by the presence of atypical melanocytes: 
• melanocytes, located on the entire thickness of the epider-
mis, are irregularly placed, creating pagetoid-like groups 
(superficial spreading melanoma in situ); or: 
• in the basal layers of epidermis, placed in a linear and 
lentiginal way (lentigo melanoma in situ). 
In the case of melanoma in situ and/ or accompanying mela-
nocyte infiltration in the upper layers of the skin, the prognosis is 
defined as very good. The phase of melanoma growth is defined 
as the radial growth phase (RGP). It precedes the melanoma’s 
progression into the skin, a process which consists in transgres-
sing the basal membrane of the epidermis and an infiltration into 
the lower skin layers with the creation of a nodule. This stage is 
defined as  the vertical growth phase (VGP). It is connected with 
the progression of a lesion and has a poor prognosis.
The creators of the most recent classification of skin tu-
mours, the “WHO Classification of Skin Tumours 4th edition, 
2018” [3] point to two basic types of melanoma: melanomas 
with the radial phase and those which since their onset  begin 
to develop in a vertical way. The first group comprises: a su-
perficial spreading melanoma and a malignant lentigo. The 
other group comprises nodular melanoma, which has only 
a vertical phase and naevoid melanoma, which usually does 
not have a radial phase. 
The above listed melanoma groups differ from one another 
in terms of  their ontogenetic mechanisms, and the genetic 
changes occurring within them as well as their clinical picture. 
The main ontogenetic mechanism is the damage caused by 
the UV radiation connected with exposure to the sun  (or arti-
ficial UV radiation). High-energy UVB rays, which make up 5% 
of the radiation which reaches the Earth, penetrate the skin, 
damaging the epidermis and causing tumours. 
The most recent WHO classification proposes the division 
into the skin melanomas based on the factors which cause 
the disease:
• significant damage to the skin resulting from a cumulative 
dose of sun radiation (high cumulative skin damage, high-
-CSD melanoma); 
• and slight damage to the skin caused by a small or spora-
dic UV exposure (low cumulative skin damage, low-CSD 
melanoma). 
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The first group of melanomas contains a large number of 
punt mutations; in particular the mutations in the following 
genes are typical: NF1, NRAS, BRAF (other than p. V600E), KIT 
(MAPK activation pathway), TP53. Melanomas of the skin which 
have been chronically exposed to sun (high-CSD melano-
ma/melanocytic tumours in chronically sun-exposed skin) 
comprise: lentigo malignant melanomas and desmoplastic 
melanomas. In the low-CSD melanomas, the mutation in the 
codon 600 BRAF gene is dominating (BRAF p. V600E). This 
group is also comprised of the low-CSD melanoma/superficial 
spreading melanoma. 
There is also a group of melanomas that have no con-
nection to UV exposure. These are: acral melanoma, mucosal 
melanoma, uveal melanomas and Spitz melanomas. In these 
melanomas, the following gene mutations are detected: HRAS 
(Spitz melanoma), KIT, NRAS, BRAF, HRAS, KRAS, ALK, NTRK3 (acral 
melanoma), KIT, NRAS, KRAS (mucosal melanoma) and GNAQ, 
GNA11, CYSLTR2 (uveal melanoma).
Moreover, in all three types of these melanomas, there is 
a mutation of the CDKN2A gene, coding p16 protein which 
performs the function of a tumour suppressor within a cell. 
The loss of p16 expression in the immunohistochemical reac-
tion is a proof of the presence of melanoma, and this is why 
the quantification of this protein is used in histopathological 
deferential diagnosis [4, 5]. A detailed list of genetic changes 
occurring in specific types of melanocyte proliferations is pre-
sented in figure 1.
Apart from the above-listed mutations, high-CSD melano-
mas contain a very high mutation burden, whilst, for example, 
in acral melanomas and mucosal melanomas the mutation 
burden is low, and in uveal melanomas – even lower. Amongst 
many genetic anomalies, the mutations of the BRAF V600E and 
C-KIT genes have predictive significance – and for this reason 
the tissue material containing the cell pattern of the primary or 
metastatic melanoma is assessed with regards to the presence 
of these mutations.
Another difficult group with respect to diagnostics com-
prises melanocytic lesions of the Spitz type, with their mali-
gnant form being Spitz melanoma/malignant Spitz tumour). 
A malignant form of melanocytic proliferations of the skin of 
the limbs is subungual melanomas of the limbs. Other types 
which have been distinguished are mucosal melanomas/geni-
tal, oral, sino-nasal melanomas), including mucosallentiginous 
melanomas and mucosalnodular melanomas. Melanomas 
Melanocytic tumours in intermittently sun-exposed skin
low-CSD melanoma (superficial spreading melanoma)
simple lentigo and lentiginous melanocytic naevus
junctional naevus
compound naevus
dermal naevus
dysplastic naevus
naevus spilus
special-site naevi (of the breast, axilla, scalp and ear)
halo naevus
Meyerson naevus
recurrent naevus
deep penetrating naevus
pigmented epithelioid melanocytoma
combined naevus, including combined BAP1-inactivated naevus/
melanocytoma
Melanocytic tumours in chronically sun-exposed skin
lentigo maligna melanoma
desmoplastic melanoma
Spitz tumours
malignant Spitz tumour (Spitz melanoma)
Spitz naevus
pigmented spindle cell naevus (reed naevus)
Melanocytic tumours in acral skin
acral melanoma
acral naevus
Genital and mucosal melanocytic tumours
mucosal melanomas (genital, oral, sinonasal)
          mucosal lentiginous melanoma
          mucosal nodular melanoma
genital naevus
Melanocytic tumours arising in blue naevus
melanoma arising in blue naevus
blue naevus NOS
cellular blue naevus
mongolian spot
naevus of Ito 
naevus of Ota
Melanocytic tumours arising in congenital naevi
melanoma arising in giant congenital naevus
congenital melanocytic naevus
proliferative nodules in congenital melanocytic naevus
Ocular melanocytic tumours
uveal melanoma
          epithelioid cell melanoma
          spindle cell melanoma, type A
          spindle cell melanoma, type B
conjunctival melanoma
          melanoma NOS
conjunctival primary acquired melanosis with atypia/melanoma in situ
conjunctival naevus
Nodular, naevoid and metastatic melanomas
nodular melanoma
naevoid melanoma
metastatic melanoma
Table I. Division of the tumours arising from melanocytes according to the WHO classification from 2018
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can also be a malignant form of tumour arising in the blue 
naevus or rising in giant congenital naevus. A separate group 
is made by ocular melanocytic tumours, comprised of uveal 
melanomas and conjunctival melanomas. The last group is 
comprised of nodular melanomas, naevoid melanomas, and 
metastatic melanomas. The current classification of melano-
cytic proliferations is presented in table I.
The above classification specifies melanocytic prolifera-
tions in a traditional way, dividing  them into benign and 
malignant lesions. Yet, as is the case with other tumours (for 
examples ovarian tumours or soft tissue carcinomas), the au-
thors of the current classification “legalise” the terms which 
were previously used by dermatologists to describe the lesions 
with uncertain malignancy potential. This is the outcome of 
a belief that it is not always possible to definitely determine the 
potential of a lesion malignancy on the basis of morphologic 
features, immuno-profiling, and genetic changes. 
The WHO classification from 2018 presents definitions and 
terms used for the description of melanocytic tumours of un-
certain malignant potential (MELTUMP). Atypical melanocyte 
proliferation in the skin means that a lesion has the potential 
for vertical growth (tumorigenic), yet there are no definite cri-
teria which would allow one to determine whether this lesion 
is benign or malignant. Also superficial atypical melanocytic 
proliferations of unknown significance (SAMPUS) were defined 
as atypical melanocytic proliferations localised in the epidermis 
and upper layer of the skin. Such a lesion cannot be definitely 
specified on the basis of a microscopic image, neither can the 
melanoma radial phase be excluded. In other words, SAMPUS 
is an atypical proliferation of pigment cells with the thickness 
of 0.8 mm, without ulceration in which deep maturation and 
symmetry are difficult to determine (which is understanda-
ble); also this proliferation lacks other typical morphological 
features typical for melanoma, such as mitotic activity. From 
a practical point of view, the therapeutic approach in both 
forms of melanocytic lesions is identical and consists of en-
larging the surgical margin (the so-called wide resection of 
the scar). A differential diagnosis of SAMPUS is very difficult, 
especially when a skin specimen does not contain the entire 
lesion, is not optimally fixed or if there are some features of 
regression. It must be remembered that both “over-diagnosing” 
and “under-diagnosing” melanoma may lead to serious legal 
consequences for a pathomorphologist. 
In the case of MELTUMP, there is always a chance that this 
is an atypical malignant proliferation of melanocytes which is 
potentially capable of producing metastases, and even life-
-threatening for a patient. To sum up, the term, “uncertain 
significance” in reference to the lesions of the SAMPUS or IAM-
PUS type (intraepidermal atypical melanocytic proliferation of 
uncertain significance) means only the possibility of a relapse 
or progression whilst the term “uncertain malignancy potential” 
in the case of MELTUMP means that a malignant course of the 
disease cannot be excluded. A differential diagnosis of  MEL-
TUMP always comprises a melanoma and histopathological 
assessment and should always contain a statement that, for 
example, this is “a lesion intermediate between a blue naevus 
and melanoma arising from a blue naevus”. 
The above diagnoses are descriptive and provisional, which 
means that one must always try to establish a precise and 
definite histopathological diagnosis. In a differential diagnosis, 
apart from a thorough microscopic assessment of the speci-
men routinely dyed with  haematoxylin-eosin, the authors of 
the most recent classification recommend the use of immu-
nohistochemical reactions, including HMB45, Ki-67 and p16. 
Immunohistochemical loss of the p16 protein usually signifies 
melanoma, yet in some cases, in which CDKN2A deletion 
does not occur within the melanoma ontogenetic pathway, 
a strongly preserved reaction with p16 is seen [7]. BRAF and 
NRAS gene mutations, frequently present in melanoma, are 
unfortunately also present in benign lesions. Therefore they 
do not have any diagnostic significance. 
According to the 8th edition of the classification of patholo-
gical stages of melanoma (pTNM) worked out by the American 
Joint Committee on Cancer/Union for International Cancer 
Control (AJCC/UICC) from 2017, the assessment of a melanoma 
stage is based on two microscopic properties with the largest 
prognostic significance, i.e. the depth of infiltration and the 
presence of ulceration. The evaluation of an additional factor 
in pT1, i.e. mitotic activity in the vertical phase (present in the 
previous, 7th edition of the classification pTNM/AJCC/UICC) 
was abandoned. It must be emphasised that the correlation 
between mitotic activity and the frequency of metastases 
formation in lymph nodes was shown [6]. Yet, in comparison 
with the previous edition, the presence of the figures of cellular 
division in the vertical phase of thin melanomas does not mean 
the change of tumour stage from pT1a to pT1b. In spite of this, 
mitotic activity still remains a significant prognostic factor and 
should form a part of the histopathological diagnosis. Currently 
the “demarcation point” for thin melanomas is regarded to be 
a depth of 0.8 mm and with a lack of ulceration. From a clinical 
point of view, these lesions are treated as locally advanced and 
do not require  the sentinel node procedure to be performed. 
Table II. Primary melanoma staging with regards to T feature 
pT Lesion depth according to Breslow’s classification 
pT1a Infiltration depth ≤0.8 mm, no ulceration 
pT1b Infiltration depth ≤0.8 mm, ulceration (+) or infiltration 
to the depth of 0.8–1 mm 
pT2a Infiltration depth >1–2 mm, ulceration (–)
pT2b Infiltration depth >1–2 mm, ulceration (+)
pT3a Infiltration depth >2–4 mm, ulceration (–)
pT3b Infiltration depth >2–4 mm, ulceration (+)
pT4a Infiltration depth >4 mm, ulceration (–)
pT4b Infiltration depth >4 mm, ulceration (+)
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Table II presents the stages of the primary melanoma according 
to the 8th edition  of pTNM AJCC/UICC classification from 2017. 
According to this classification, the pN stage specifies the 
melanoma metastases in lymph nodes (irrespective of their size 
and the number of tumour cells), microsatellite foci, satellite 
or in-transit metastases in lymph node(s) above 0 (pN > 0). 
In order to make a credible evaluation of lymph node status, 
at least six lymph nodes must be assessed. Not finding the 
melanoma metastasis in a lower number of the examined 
lymph nodes must also be classified as pN0 (like in the case 
of the evaluation of six or more lymph nodes). If no complete 
lymphadenectomy was performed, the histopathological re-
port should contain a note that the classification is based only 
on the microscopic assessment of the sentinel node(s) – for 
example: pN0 (sn). 
The current classification of the pN stage distinguishes 
the patients with clinically occult metastases. Such lesions, in 
a situation when no microsatellite or satellite foci or in transit 
metastases are found, are classified as N1a, N2a, N3a stage – de-
pending on the number of the lymph nodes.  When the above 
satellite foci or in transit metastases are present, yet without 
the metastases in the lymph nodes, the pN stage is qualified 
as N1c, N2c, N3c respectively – depending on the number 
of lymph nodes involved. But in the case of clinically evident 
metastases in the lymph nodes and without the presence 
of microsatellite or satellite foci or in transit metastases, the 
pN stage is evaluated to be pN1b, pN2b, pN3b – depending 
on the number of lymph nodes involved. In the 7th and 8th 
classification  of TNM AJCC/UICC [8], the N stage is evaluated 
differently. However, the detection of a distant melanoma 
metastasis in a microscopic assessment is marked with the 
M1 symbol – as in the previous classifications. 
The most recent WHO classification of skin cancers, similar-
ly to the previous editions, emphasises the role of microscopic 
assessment. This classification presents detailed criteria, defi-
nitions, and terms used in the daily histopathological practice 
of assessing skin cancers, including melanoma. The pTNM 
AJCC/UICC classification, takes into consideration the role 
of the pathomorphological examination. This classification 
specifies the tumour stages based on significant prognostic 
factors. The update of the histopathological WHO classification 
and of the pTNM AJCC/UICC stages is the outcome of the 
developments in the studies of melanoma pathogenesis and 
epidemiological data. 
All the microscopic parameters (apart from the histological 
type of melanoma) which have prognostic significance and 
which are useful for the selection of the treatment method, 
and which need to be obligatorily evaluated and stated in the 
histopathological  report comprise: the depth of infiltration, 
the presence of ulceration and microsatellite or satellite foci 
or in-transit metastases. They determine the pTNM AJCC/UICC 
tumour stage. 
Significant progress in access to new therapeutic methods 
of targeted therapies has been made in recent years; this has 
contributed to the increase in the importance of molecu-
lar tests – not only in the understanding of the process of 
oncogenesis, but also in the detection of predictive factors 
in personalised therapies. Therefore, a pathomorphological 
report should consider significant microscopic prognostic 
factors and predictive molecular markers.
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